Liver function study for myeloma drug cancelled before it began
NCT ID NCT04398680
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a Phase 1 study designed to see how the drug belantamab mafodotin behaves in people with multiple myeloma who also have liver impairment. The goal was to check safety and drug levels in the blood. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin
What could go wrong
The study was withdrawn before any participants were enrolled, so no data was collected. It is unclear if this treatment will be safe or effective for patients with liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Tucson, Arizona, 85724, United States
-
GSK Investigational Site
Beverly Hills, California, 90211, United States
-
GSK Investigational Site
Plantation, Florida, 33322, United States
-
GSK Investigational Site
Wichita, Kansas, 67214, United States
-
GSK Investigational Site
Baltimore, Maryland, 21201-1595, United States
-
GSK Investigational Site
Monroeville, Pennsylvania, 15146, United States
-
GSK Investigational Site
The Woodlands, Texas, 77380, United States
-
GSK Investigational Site
Milwaukee, Wisconsin, 53233, United States
-
GSK Investigational Site
Athens, 10676, Greece
-
GSK Investigational Site
Daegu, 41944, South Korea
-
GSK Investigational Site
Hwasun, 58128, South Korea
-
GSK Investigational Site
Incheon, 405-760, South Korea
-
GSK Investigational Site
Jeonju, 561-172, South Korea
-
GSK Investigational Site
Pusan, 49241, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Seoul, 120-752, South Korea
-
GSK Investigational Site
Suwon Kyunggi-do, 16499, South Korea